BIAFW — bioAffinity Technologies, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1712762 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,351,527 | 422,891 | -3,616,976 | -3,630,610 | 7,945,252 | 3,098,366 | 4,283,866 |
| Dec 2025 | 1,538,813 | 638,687 | -3,190,963 | -3,137,466 | 10,960,772 | 6,449,782 | 3,683,116 |
| Sep 2025 | 1,446,066 | 503,855 | -2,292,846 | -5,051,084 | 11,546,369 | 7,669,195 | 2,644,171 |
| Jun 2025 | 1,269,483 | 252,881 | -2,515,560 | -4,060,787 | 4,751,075 | 802,835 | 6,887,183 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,328,842
Investing CF
$-60,568
Financing CF
$14,733,901
CapEx
$-64,215
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-68,554,064
Inventory
$53,548
Receivables
$541,962
ST Investments
—
EBIT TTM
$-14,821,340
Pretax Income TTM
$-14,865,712
Interest Exp TTM
$44,372
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,659,889
EBITDA
$-10,989,645
Free Cash Flow
—
Enterprise Value
—
Total Cash
$3,098,366
Total Debt
$1,382,591
Shares Out
—
Trailing EPS
—
Book Value
$1.62
ROE
-622.6%
ROA
-107.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,107,959 | -10,626,508 | -14,909,754 | 10,960,772 | 3,683,116 | — | -9,328,842 |
| Dec 2024 | 9,362,022 | -8,953,445 | -9,039,831 | 6,513,667 | 3,911,631 | — | -7,264,795 |
| Dec 2023 | 2,532,499 | -7,973,228 | -7,937,011 | 8,221,552 | 3,366,297 | — | -6,037,806 |
| Dec 2022 | 4,803 | -4,011,058 | -8,154,113 | 12,182,125 | 1,138,682 | — | -4,070,845 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $43.95B | $557.21 | — |
| IQV | IQVIA HOLDINGS INC. | $27.04B | $162.00 | — |
| INCY | INCYTE CORP | $19.40B | $97.10 | — |
| MEDP | Medpace Holdings, Inc. | $12.26B | $429.11 | — |
| ICLR | ICON PLC | $8.69B | $113.85 | — |
News headlines (Yahoo Finance, 1h cache)
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung
2026-05-14 14:27 · Yahoo
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
2026-05-12 13:15 · Yahoo
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
2026-05-08 12:30 · Yahoo
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
2026-04-28 13:16 · Yahoo
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
2026-04-16 13:55 · Yahoo
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
2026-04-14 12:00 · Yahoo
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16
2026-04-07 12:00 · Yahoo
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
2026-04-01 12:00 · Yahoo
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
2026-03-25 12:00 · Yahoo
BC-Most Active Stocks
2026-03-23 14:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.